These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 21392722)
1. The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. Hoenig MR; Walker PJ; Gurnsey C; Beadle K; Johnson L J Clin Lipidol; 2011; 5(2):91-6. PubMed ID: 21392722 [TBL] [Abstract][Full Text] [Related]
2. Physiogenomic association of statin-related myalgia to serotonin receptors. Ruaño G; Thompson PD; Windemuth A; Seip RL; Dande A; Sorokin A; Kocherla M; Smith A; Holford TR; Wu AH Muscle Nerve; 2007 Sep; 36(3):329-35. PubMed ID: 17600820 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. McKenney JM; Davidson MH; Shear CL; Revkin JH J Am Coll Cardiol; 2006 Nov; 48(9):1782-90. PubMed ID: 17084250 [TBL] [Abstract][Full Text] [Related]
5. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Strandberg TE; Feely J; Sigurdsson EL; Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694 [TBL] [Abstract][Full Text] [Related]
6. Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin. Cerda A; Genvigir FD; Arazi SS; Hirata MH; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD Clin Chim Acta; 2010 May; 411(9-10):631-7. PubMed ID: 20064494 [TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Kajinami K; Brousseau ME; Ordovas JM; Schaefer EJ Am J Cardiol; 2004 Apr; 93(8):1046-50. PubMed ID: 15081455 [TBL] [Abstract][Full Text] [Related]
8. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E; Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231 [TBL] [Abstract][Full Text] [Related]
9. ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Rebecchi IM; Rodrigues AC; Arazi SS; Genvigir FD; Willrich MA; Hirata MH; Soares SA; Bertolami MC; Faludi AA; Bernik MM; Dorea EL; Dagli ML; Avanzo JL; Hirata RD Biochem Pharmacol; 2009 Jan; 77(1):66-75. PubMed ID: 18851956 [TBL] [Abstract][Full Text] [Related]
10. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients. Joy MS; Dornbrook-Lavender KA; Chin H; Hogan SL; Denu-Ciocca C Ann Pharmacother; 2008 Jan; 42(1):9-15. PubMed ID: 18000162 [TBL] [Abstract][Full Text] [Related]
11. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis. Kuryata OV; Yegorova YV Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629 [TBL] [Abstract][Full Text] [Related]
12. Effect of the TNFalpha-308 G/A polymorphism on the changes produced by atorvastatin in bone mineral density in patients with acute coronary syndrome. Pérez-Castrillón JL; Vega G; Abad L; Sanz-Cantalapiedra A; Gonzalez Sagredo M; de Luis D; Duenas-Laita A Ann Nutr Metab; 2008; 53(2):117-21. PubMed ID: 18997459 [TBL] [Abstract][Full Text] [Related]
13. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. Wlodarczyk J; Sullivan D; Smith M Am J Cardiol; 2008 Dec; 102(12):1654-62. PubMed ID: 19064019 [TBL] [Abstract][Full Text] [Related]
14. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk. Velussi M Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Leiter LA; Bays H; Conard S; Bird S; Rubino J; Hanson ME; Tomassini JE; Tershakovec AM Am J Cardiol; 2008 Dec; 102(11):1495-501. PubMed ID: 19026303 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310 [TBL] [Abstract][Full Text] [Related]
17. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study. Farsang C; Athyros V; Gaw A; Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H; Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314 [TBL] [Abstract][Full Text] [Related]
19. Association between ABCB1 C3435T polymorphism and increased risk of cannabis dependence. Benyamina A; Bonhomme-Faivre L; Picard V; Sabbagh A; Richard D; Blecha L; Rahioui H; Karila L; Lukasiewicz M; Farinotti R; Picard V; Marill C; Reynaud M Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1270-4. PubMed ID: 19625010 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Conard SE; Bays HE; Leiter LA; Bird SR; Rubino J; Lowe RS; Tomassini JE; Tershakovec AM Am J Cardiol; 2008 Dec; 102(11):1489-94. PubMed ID: 19026302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]